MODE 2: Post-Acquisition Integration & Strategy (投后整合与战略规划)
Project Tengen | IASO Bio × Medisix Therapeutics
Date: 2026-03-20 | Classification: CONFIDENTIAL
1. Integration Master Plan (整合总体规划)
1.1 Integration Philosophy & Governance (整合理念与治理)
Integration Approach: Hybrid Model — Operational Integration with Regional Autonomy
| Dimension |
Approach |
Rationale |
| R&D / Science |
Full integration — PEBL programs under IASO CSO |
Leverage IASO's R&D infrastructure; critical mass |
| Clinical Operations (EU) |
Stand-alone with coordination — OPBG managed locally |
Locatelli/academic relationships require independence |
| Manufacturing |
Full integration — IASO CMC team leads |
Rebuild manufacturing chain using IASO facilities |
| Regulatory |
Full integration — IASO global regulatory team |
IASO has 12+ country experience |
| Commercial |
Integrated — PEBL products in IASO global commercial strategy |
Leverage existing hospital/distributor relationships |
| Corporate (SG entity) |
Maintained as subsidiary — operational shell |
NUS license, JTC lease, SG regulatory status |
| Finance/HR/IT |
Full integration — merge into IASO |
Eliminate standalone overhead |
Integration Management Office (IMO) Structure
┌─────────────────────────────────────┐
│ Integration Steering Committee │
│ Chair: Zhang Jinhua (IASO CEO) │
│ Members: CSO, CFO, CCO, CMO │
│ Frequency: Bi-weekly → Monthly │
└───────────────┬─────────────────────┘
│
┌───────────┴───────────┐
│ IMO Director │
│ (Dedicated full-time) │
└───────────┬───────────┘
│
┌───────┬───┴───┬───────┬──────┐
│ │ │ │ │
R&D CMC Clinical Legal Finance
Lead Lead Lead Lead Lead
Decision Rights Framework
| Decision Category |
Singapore (Local) |
China (Central) |
| NUS license management |
✅ Execute |
✅ Approve |
| OPBG clinical protocol |
✅ Execute |
⚠️ Inform |
| JTC lease operations |
✅ Execute |
⚠️ Inform |
| SG regulatory filings |
✅ Execute |
✅ Approve |
| R&D priorities / pipeline decisions |
⚠️ Input |
✅ Decide |
| Manufacturing process development |
⚠️ Input |
✅ Decide |
| Budget > $500K |
⚠️ Propose |
✅ Approve |
| Hiring (SG) |
✅ Execute (< $150K/yr) |
✅ Approve (≥ $150K/yr) |
| IP filings |
⚠️ Propose |
✅ Approve |
| External communications |
⚠️ Draft |
✅ Approve |
Communication Plan
| Audience |
Message |
Channel |
Timing |
Owner |
| Medisix employees (4) |
Retention commitment; role clarity; IASO vision |
In-person (SG) + written offer |
Day 1 |
HR / IMO Director |
| Dario Campana |
Strategic importance; retention package; expanded role |
1:1 with IASO CEO |
Pre-closing |
CEO |
| Franco Locatelli / OPBG |
Commitment to clinical program; expanded resources; academic independence |
Letter + video call |
Day 1 |
CSO / Clinical |
| NUS |
Partnership continuation; license in good standing; investment commitment |
Formal letter + meeting |
Pre-closing |
Legal / BD |
| CPN holders / investors |
Restructuring terms; consideration structure |
Legal communication |
Pre-closing |
CFO / Legal |
| JTC |
Change of control notification; continued operations |
Formal application |
Pre-closing |
SG Legal |
| WuXi ATU |
Transition plan; continued stability testing; data handover |
Written notice |
Day 1 |
CMC |
| IASO employees |
Acquisition rationale; no impact on existing programs; pipeline expansion |
Town hall + written memo |
Day 1 |
CEO / HR |
| Media / Public |
Strategic acquisition; pipeline expansion; global ambition |
Press release (bilingual EN/ZH) |
At closing |
Corporate Communications |
| Regulators (HSA, EMA) |
Change of control notification; commitment to ongoing trials |
Formal submissions |
Per regulatory timeline |
Regulatory |
1.2 Day 1 Readiness (第一天准备)
| # |
Activity |
Owner |
Status Required by Day 1 |
| 1 |
Legal entity ownership transfer recorded with ACRA (SG) and Delaware SoS (US) |
Legal |
Filed |
| 2 |
Bank accounts: IASO signatory authority on MT SG and MT Inc accounts |
CFO |
Active |
| 3 |
IT access: IASO IT team has admin access to all Medisix systems (Benchling, email, cloud) |
IT |
Complete |
| 4 |
Employee communications delivered; retention packages activated |
HR |
Delivered |
| 5 |
Campana retention agreement effective |
HR / Legal |
Signed |
| 6 |
Locatelli / OPBG notification letter sent |
Clinical |
Sent |
| 7 |
Insurance policies in effect (D&O, clinical trial, professional indemnity) |
Legal / Finance |
Bound |
| 8 |
NUS amendment effective |
Legal |
Executed |
| 9 |
IMO Director appointed and in-country (SG) |
CEO |
In position |
| 10 |
Integration playbook distributed to all workstream leads |
IMO |
Distributed |
1.3 First 100 Days Critical Path (前100天关键路径)
WEEK: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
│ │ │ │ │ │ │ │ │ │ │ │ │ │
DAY 1 ├── Employee retention ──────────┤
COMMS ├── Stakeholder notifications ───┤
│
LEGAL ├── Entity registrations ─────┤
│ ├── Insurance placement ──┤
│ ├── IP assignment cleanup ──────────┤
│
R&D ├── Campana workplan alignment ──────────┤
│ ├── CD99 preclinical design ─────────────────────────────┤
│ ├── IASO antibody library screening (CD99/CD70) ────┤
│
CMC ├── LVV process assessment ─────────────┤
│ ├── Plasmid remanufacture RFP ──────┤
│ ├── IASO facility allocation ──────────────┤
│ ├── WuXi data handover negotiation ──────────┤
│
CLIN ├── OPBG collaboration agreement ───────────────┤
│ ├── Multi-center site activation (FR/DE/NL) ──────────────────┤
│ ├── PIP preparation ──────────────────────────────────┤
│
REG ├── ODD application (EMA) ──────────────┤
│ ├── PRIME application ─────────────────────┤
│ ├── US IND strategy development ──────────────────────┤
│
FIN ├── Reporting consolidation ────────────┤
│ ├── Transfer pricing restructure ──────────────────────┤
│ ├── Tax loss utilization plan ────────────────────────┤
│
HR ├── Knowledge transfer (Cecilia) ───────────────────────────────┤
│ ├── SG team staffing plan ─────────────────────────┤
2. Functional Integration Workstreams (职能整合工作流)
2.1 R&D / Technology (研发/技术)
| Dimension |
Current State |
Target State |
Transition Plan |
Timeline |
KPIs |
Risk |
| PEBL R&D leadership |
Campana (part-time, $75K/quarter) |
Campana as SAB Chair + dedicated IASO R&D team lead (Dr. Zhang Yongke CSO oversight) |
Engage Campana in expanded advisory role; assign IASO scientists to PEBL |
Month 1-3 |
Campana hours/month; new constructs designed |
Campana disengagement |
| CD99 program |
Not started (planned) |
IND-ready preclinical package |
Campana designs constructs; IASO antibody library screens binders; in vitro and in vivo studies at IASO Nanjing |
Month 1-18 |
Construct candidates identified (M3); in vitro data (M6); in vivo data (M12); IND package (M18) |
Biology failure; timeline slip |
| CD70 program |
Not started (planned) |
Lead candidate selection |
Parallel with CD99; broader screening given multiple indication potential |
Month 3-24 |
Target validation (M6); construct design (M12); lead selection (M24) |
Lower priority; resource competition |
| PCART7 optimization |
Clinical construct (OPBG) |
Optimized commercial construct |
Evaluate scFv humanization; optimize vector design; align with IASO manufacturing |
Month 3-12 |
Optimized construct (M9); comparability data (M12) |
Process change regulatory impact |
| In vivo CAR-T × PEBL |
Separate programs (IASO in vivo + Medisix PEBL) |
Combined in vivo PEBL platform for T-cell malignancies |
IASO in vivo team (Dr. Zhang Yongke) + Campana PEBL → joint research program |
Month 6-36 |
Proof-of-concept in vitro (M12); in vivo data (M24) |
High scientific risk; novel combination |
2.2 CMC / Manufacturing (生产制造)
| Dimension |
Current State |
Target State |
Transition Plan |
Timeline |
KPIs |
Risk |
| LVV production |
WuXi ATU (expired MSA); OXGENET proprietary process; single-source dependency |
IASO in-house LVV production (Nanjing or Waigaoqiao) |
(1) Remanufacture plasmids at Aldveron or equivalent; (2) Develop suspension LVV process at IASO; (3) Scale-up and GMP validation; (4) Bridging study if required |
Month 1-24 |
Plasmid remanufactured (M3); process development complete (M12); GMP batch (M18); validation (M24) |
🔴 Critical path; longest lead time |
| CAR-T manufacturing |
OPBG G-Rex (academic, semi-open) |
IASO GMP automated process (Nanjing Module 4 or Waigaoqiao) |
(1) Tech transfer from OPBG; (2) Adapt to IASO platform; (3) Process comparability; (4) GMP validation |
Month 3-18 |
Tech transfer complete (M6); comparability data (M12); GMP validation (M18) |
Process change = regulatory impact |
| Quality system |
None at Medisix; OPBG academic QA |
Integrated into IASO QA/QC system |
(1) Establish PEBL product specifications; (2) Analytical methods transfer; (3) Stability program; (4) QA documentation |
Month 1-12 |
Specifications approved (M3); methods validated (M6); stability initiated (M9) |
Low — IASO has existing QMS |
| Supply chain |
WuXi (plasmids, LVV); Alcami (storage); no logistics |
Integrated into IASO supply chain (Andy, SVP) |
(1) Inventory audit; (2) Storage consolidation; (3) Cold chain logistics setup for OPBG clinical supply |
Month 1-6 |
Inventory confirmed (M1); logistics established (M3); supply agreement with OPBG (M6) |
Low |
2.3 Clinical Operations (临床运营)
| Dimension |
Current State |
Target State |
Transition Plan |
Timeline |
KPIs |
Risk |
| OPBG Phase I/II |
11 patients enrolled; recommended dose established; Locatelli leads |
23+ patients; multi-center; CMA-ready dataset |
(1) Clinical collaboration agreement with OPBG; (2) Activate expansion sites (FR, DE, NL); (3) Accelerate enrollment |
Month 1-12 |
15 pts enrolled (M6); 23 pts enrolled (M12); dataset lock (M18) |
Enrollment pace; site activation delays |
| Multi-center expansion |
Planned but not initiated (FR: Robert Debré; NL: Princess Máxima; DE: Charité) |
Active sites with ethics approval and first patient dosed |
(1) IASO clinical team supports site activation; (2) TMC Pharma CRO coordinates; (3) LVV supply chain to new sites |
Month 1-9 |
Ethics approvals (M3); first site open (M6); first patient dosed (M9) |
Regulatory delays per country |
| Data management |
OPBG owns data (Clause 7.1); limited data access |
Joint data ownership or perpetual license; CMA-grade dataset |
(1) Negotiate data access/ownership with OPBG; (2) Establish clinical data management system; (3) Statistical analysis plan for CMA |
Month 1-6 |
Data agreement signed (M3); SAP finalized (M6) |
OPBG may resist data transfer |
| Pharmacovigilance |
TMC Pharma (limited scope) |
Integrated IASO PV system |
(1) IASO PV team assumes oversight; (2) SUSAR reporting procedures; (3) 15-year follow-up plan designed |
Month 1-6 |
PV transfer complete (M3); follow-up plan approved (M6) |
Low |
2.4 Regulatory (监管注册)
| Dimension |
Current State |
Target State |
Transition Plan |
Timeline |
KPIs |
| EMA CMA pathway |
Scientific advice obtained; no formal applications |
PIP filed; ODD granted; PRIME designation; CMA application in preparation |
IASO regulatory team (Ren Chunli) leads: (1) ODD application M1; (2) PIP application M3; (3) PRIME application M6; (4) CMA dossier preparation M12+ |
Month 1-24+ |
ODD granted (M6); PIP approved (M12); CMA filing (M24-30) |
| US FDA |
No interaction |
Pre-IND meeting completed; IND strategy defined |
(1) Pre-IND meeting request M6; (2) Meeting M9; (3) IND preparation M12-18 |
Month 6-18 |
Pre-IND feedback (M9); IND filing decision (M12) |
| China NMPA |
No interaction |
China clinical strategy defined |
(1) Assess bridging study requirements M3; (2) Pre-IND consultation M6; (3) Focus on CD99/CD70 for China (broader market) |
Month 3-12 |
Strategy document approved (M6) |
| Singapore HSA |
Historical data (17 pts at NUH) |
HSA notification of change; potential Class 2 CTGTP pathway evaluation |
(1) Notify HSA of corporate change M1; (2) Evaluate PCART7 conditional registration pathway M3 |
Month 1-6 |
HSA notified (M1) |
2.5 Finance (财务)
| Dimension |
Current State |
Target State |
Transition Plan |
Timeline |
| Reporting |
Separate MT Inc (US GAAP) + MT SG (SFRS) |
Consolidated under IASO (IFRS) |
(1) Align chart of accounts M1; (2) Consolidation model M3; (3) First consolidated report M6 |
Month 1-6 |
| Transfer pricing |
Cost + 7% (low end); intercompany loan undocumented |
Arm's length TP at median range (13-15%); loan capitalized |
(1) Capitalize $12M loan at closing; (2) New TP policy and documentation M3; (3) Engage Big 4 for benchmark study M6 |
Month 0-6 |
| Treasury |
Separate bank accounts; multi-currency |
Integrated cash pooling through IASO treasury |
(1) Add IASO signatories Day 1; (2) Evaluate cash pooling M3; (3) FX hedging for EUR clinical costs M1 |
Month 0-3 |
| Tax |
SG losses SGD 17.4M; US losses $41.3M |
Optimize loss utilization; proper TP documentation |
(1) SG tax advisor confirms loss carryforward post-acquisition; (2) US Section 382 analysis for NOL utilization; (3) Ongoing tax compliance structure |
Month 1-6 |
2.6 HR / People (人力资源)
| Dimension |
Current State |
Target State |
Transition Plan |
Timeline |
| SG team |
4 employees + 2 consultants |
6-8 FTEs (add: QA specialist, R&D scientist, operations manager) |
(1) Retain existing 4 employees; (2) Hire 2-4 additional per needs assessment M3; (3) Align comp to IASO bands |
Month 1-6 |
| Key retention |
No retention packages |
Campana ($1-2M package), Cecilia ($100-200K), Bruce (current terms) |
(1) Campana agreement pre-close; (2) Cecilia retention bonus Day 1; (3) Bruce assessment M3 |
Month 0-3 |
| Culture integration |
Academic/startup culture |
Hybrid: academic freedom for science + IASO execution discipline |
(1) Cross-cultural workshop M1; (2) Joint team meetings monthly; (3) SG team visits to Nanjing M3 |
Ongoing |
| Employment compliance |
"At-will" clauses (non-compliant SG) |
SG Employment Act compliant contracts |
(1) Engage SG employment lawyer M1; (2) Issue new compliant contracts M2 |
Month 1-2 |
2.7 Legal / Compliance (法律/合规)
| Dimension |
Current State |
Target State |
Transition Plan |
Timeline |
| Entity structure |
MT Inc (USA) → MT SG |
Metis Bio (SG SPV) → MT Inc (USA) → MT SG |
ACRA filings; Delaware SoS filings; update all registrations |
Month 0-1 |
| IP assignments |
Campana AML patent unassigned; Cecilia Sim no PIA |
All IP properly assigned; all employees/contractors have PIAs |
(1) Campana AML patent assignment; (2) PIAs for all personnel; (3) Patent assignment updates with USPTO/EPO |
Month 0-3 |
| Insurance |
Missing D&O, clinical trial, product liability, cyber |
Full coverage suite |
(1) D&O and clinical trial insurance Day 1; (2) Product liability when nearing commercial M18; (3) Cyber M3 |
Month 0-18 |
| Contract novation |
Change of control issues (JTC, potentially NUS) |
All contracts updated/confirmed |
(1) JTC consent; (2) NUS amendment; (3) TMC notification; (4) OPBG new agreement |
Month 0-3 |
| Data privacy |
No DPAs or SCCs in place |
GDPR/PDPA/PIPL compliant data framework |
(1) DPA with OPBG M1; (2) SCCs for EU→SG data transfer M3; (3) PIPL assessment for SG→CN M3 |
Month 1-3 |
2.8 IT / Data (信息技术/数据)
| Dimension |
Current State |
Target State |
Transition Plan |
Timeline |
| Systems |
Benchling ELN; standard office IT; minimal infrastructure |
Integrated into IASO IT environment; Benchling maintained |
(1) IT security audit M1; (2) Account migration M2; (3) Benchling contract review M3 |
Month 1-3 |
| Clinical data |
OPBG-owned clinical data; limited access |
Joint data platform; CMA-grade database |
(1) Data access negotiation with OPBG M1-3; (2) Clinical database setup M3-6; (3) Data migration M6-9 |
Month 1-9 |
| Cybersecurity |
No cyber insurance; minimal security posture |
IASO cybersecurity standards applied |
(1) Vulnerability assessment M1; (2) Policy implementation M2; (3) Training M3 |
Month 1-3 |
3. Global Strategy Post-Acquisition (全球战略布局)
3.1 Combined Entity Strategic Positioning (合并后战略定位)
New positioning: China's first globally integrated cell therapy company spanning both B-cell and T-cell malignancies
| Dimension |
IASO Standalone |
IASO + Medisix |
| Target antigens |
BCMA, GPRC5D, CD19/CD22 |
+ CD7, CD99, CD70, CD3, CD5 |
| Disease coverage |
Multiple myeloma, B-NHL, B-ALL, autoimmune |
+ T-ALL, T-LBL, PTCL, AML, Ewing sarcoma |
| Technology platforms |
Autologous CAR-T, in vivo CAR-T, antibodies |
+ PEBL (fratricide-free), allogeneic (non-editing) |
| Geographic presence |
China, HK, Macau + early SG, JP, KR, MENA, RU |
+ EU (Italy, France, Germany, Netherlands), deeper SG |
| Clinical stage |
1 commercial + 9 development |
+ 1 Phase I/II (PCART7) + 5 preclinical |
| Addressable market |
~$50B (MM + B-cell + autoimmune) |
+ ~$5B (T-cell malignancies + Ewing sarcoma) |
Competitive positioning map:
AUTOLOGOUS ────────────── ALLOGENEIC
│ │
┌──────────────┼────────────────────────┤
GENE │ PersonGen │ Wugen │
EDITING │ (PEBL+NB) │ (CRISPR) │
│ │ Biocellix │
│ │ (Edit+ANSWER)│
├──────────────┼────────────────────────┤
NON-GENE │ ★ IASO+Medisix ★ ★ IASO+ │
EDITING │ (PEBL+scFv) │ Medisix ★ │
│ Best safety │ (AlloPCART7) │
│ Best efficacy│ CR w/o GVHD │
└──────────────┴────────────────────────┘
3.2 Geographic Strategy (地理布局战略)
Singapore as APAC Hub
| Function |
Why Singapore |
Investment |
| NUS license management |
License held by MT SG |
Existing |
| APAC regulatory hub |
HSA pathway for PCART7; gateway to ASEAN |
$0.5M/yr |
| APAC clinical coordination |
NUH historical data; proximity to regional hospitals |
$1M/yr |
| Tax-efficient holding |
17% CIT; extensive DTA network; no CG tax |
Structure benefit |
| Talent pool |
Biomedical sciences ecosystem; English-speaking; multicultural |
Competitive salaries |
China Operations
| Function |
Action |
Investment |
| PEBL R&D |
Nanjing R&D center — PEBL construct development, CD99/CD70 programs |
$2-3M/yr |
| LVV manufacturing |
Nanjing GMP Module 4 or Waigaoqiao — PEBL product LVV production |
$5-8M capex |
| CAR-T manufacturing |
Nanjing or Waigaoqiao — PEBL-based CAR-T commercial production |
Integrated into existing |
| Clinical (China-specific) |
CD99/CD70 focused (broader market than CD7 in China) |
$3-5M over 3 years |
| Commercial |
Leverage existing 100+ hospital network for PEBL products |
Marginal |
US/EU Expansion
| Pathway |
Strategy |
Timeline |
| EU (EMA CMA) |
PCART7 via OPBG clinical data → CMA → conditional approval |
30-36 months |
| US (FDA) |
Pre-IND → IND → Phase I/II; target BTD/RMAT/ODD |
24-36 months to IND |
| EU commercial |
Orphan drug pricing; hospital/specialist channel; potential distributor partnership |
36-48 months |
| US commercial |
Orphan drug pricing; academic medical center channel; potential licensing partner |
48-60 months |
3.3 Technology & Innovation Roadmap (技术与创新路线图)
Combined R&D Pipeline Prioritization
| Priority |
Program |
Platform |
Lead |
Budget (Yr 1-3) |
Rationale |
| P1 |
PCART7 EMA CMA |
PEBL |
IASO Clinical + Locatelli |
$5M |
De-risk lead asset; first approval |
| P2 |
CD99-PEBL preclinical→IND |
PEBL |
Campana + IASO R&D |
$8M |
Highest expert-validated commercial potential |
| P3 |
Fucaso global expansion |
IASO platform |
IASO Commercial |
Existing budget |
Revenue driver; pipeline funder |
| P4 |
CD70-PEBL preclinical |
PEBL |
IASO R&D |
$4M |
Broadest market (solid tumors) |
| P5 |
In vivo PEBL-CAR |
PEBL + IASO in vivo |
Zhang Yongke + Campana |
$3M |
Next-generation; high scientific value |
| P6 |
IASO autoimmune programs |
IASO platform |
IASO Clinical |
Existing budget |
Expanding market |
Platform Convergence Plan
YEAR 1: YEAR 2: YEAR 3:
├── PEBL constructs → ├── CD99 in vivo data → ├── CD99 IND filed
│ transferred to IASO │ CD99 IND preparation │ CD70 lead selected
│ │ │
├── LVV rebuild → ├── LVV GMP validated → ├── Commercial LVV
│ at IASO facilities │ bridging if needed │ supply chain
│ │ │
├── IASO Ab library → ├── Novel binders for → ├── Next-gen PEBL
│ screens CD99/CD70 │ CD99/CD70 selected │ constructs ready
│ │ │
├── In vivo CAR-T × ├── In vivo PEBL → ├── In vivo PEBL-CAR
│ PEBL concept design │ proof-of-concept │ IIT clinical
3.4 Go-to-Market Strategy (市场策略)
Customer Segmentation
| Segment |
Products |
Geography |
Channel |
| Pediatric hematology-oncology (T-ALL) |
PCART7 |
EU first, then US, APAC |
Academic medical centers; direct |
| Adult hematology-oncology (T-ALL/PTCL) |
PCART7, CD99-PEBL |
Global |
Academic + community oncology |
| AML (CD7+) |
PCART7 (AML expansion) |
EU, China |
Academic hematology centers |
| Ewing sarcoma (CD99+) |
CD99-PEBL |
US, EU |
Pediatric oncology centers |
| Solid tumors (CD70+) |
CD70-PEBL |
TBD |
TBD — later phase |
Cross-Sell Opportunity
| IASO Product |
Medisix Product |
Cross-Sell Opportunity |
| Fucaso (BCMA, MM) |
PCART7 (CD7, T-ALL) |
Same hematology departments; same KOLs; bundle access programs |
| IASO120 (CD19/22, B-NHL) |
CD70-PEBL (PTCL) |
Lymphoma clinics treat both B and T-cell |
| IASO782 (antibody, SLE) |
PEBL autoimmune potential |
Rheumatology cross-referral |
4. Financial Plan & Value Creation (财务规划与价值创造)
4.1 Pro Forma 5-Year P&L Projection (Medisix Contribution Only)
| Metric |
Year 1 |
Year 2 |
Year 3 |
Year 4 |
Year 5 |
| Revenue |
$0 |
$0 |
$5M |
$30M |
$80M |
| Source |
— |
— |
Named patient / compassionate use |
EU CMA launch (PCART7) |
EU + APAC ramp |
| R&D expense |
$(8M) |
$(10M) |
$(12M) |
$(10M) |
$(8M) |
| Programs |
PCART7 clinical, CD99 preclinical, LVV rebuild |
CD99 IND, CD70 preclinical, PCART7 expansion |
CD99 Phase I, CD70 IND, PCART7 multi-center |
CD99 expansion, CD70 Phase I |
Pipeline maturation |
| G&A expense |
$(3M) |
$(3M) |
$(3M) |
$(3.5M) |
$(4M) |
| Manufacturing capex |
$(5M) |
$(5M) |
$(2M) |
$(1M) |
$(1M) |
| Integration costs |
$(3M) |
$(1M) |
$0 |
$0 |
$0 |
| EBITDA |
$(19M) |
$(19M) |
$(12M) |
$15.5M |
$67M |
| Cumulative investment |
$(19M) |
$(38M) |
$(50M) |
$(34.5M) |
$32.5M |
Revenue assumptions: EU PCART7 CMA approval Year 3; 50 patients Year 3, 150 Year 4, 400 Year 5; ASP $200K; APAC launch Year 4
4.2 Synergy Realization Timeline
| Synergy |
Year 1 |
Year 2 |
Year 3 |
Year 4 |
Year 5 |
| Cost synergies (G&A consolidation) |
$1.5M |
$2.0M |
$2.0M |
$2.0M |
$2.0M |
| LVV insourcing savings |
$0 |
$0 |
$1.0M |
$1.5M |
$2.0M |
| Revenue synergies (cross-sell, accelerated launch) |
$0 |
$0 |
$2M |
$10M |
$25M |
| IPO valuation uplift |
— |
$50-100M (market cap) |
— |
— |
— |
| Total annual synergy |
$1.5M |
$2.0M |
$5.0M |
$13.5M |
$29.0M |
4.3 Value Creation Scorecard
| KPI |
Target (Year 1) |
Target (Year 3) |
Target (Year 5) |
Tracking |
| PCART7 patients enrolled |
23 |
50+ |
400+ |
Monthly |
| CD99-PEBL stage |
In vitro data |
Phase I initiated |
Phase II |
Quarterly |
| LVV in-house production |
Process development |
GMP validated |
Commercial supply |
Quarterly |
| EMA milestones |
ODD granted |
CMA filed |
CMA approved |
Per regulatory |
| Manufacturing COGS/dose |
N/A (no commercial) |
$80K target |
$60K target |
Per batch |
| Revenue (PEBL products) |
$0 |
$5M |
$80M |
Monthly |
| EBITDA contribution |
$(19M) |
$(12M) |
$67M |
Monthly |
| Patent portfolio |
116 (maintained) |
120+ (new filings) |
130+ |
Annual |
| Campana engagement |
Active (hours/month) |
Active |
Advisory |
Monthly |
5. Risk Management Post-Close (投后风险管理)
5.1 Top 10 Integration Risks — Dashboard
| # |
Risk |
RAG Status |
Trigger for Escalation |
Contingency |
| 1 |
LVV manufacturing rebuild delay |
🟡 |
>3 months behind plan |
Engage alternative CDMO (Samsung/Catalent) |
| 2 |
Campana disengagement |
🟢 |
<10 hours/month; declining responsiveness |
CEO direct intervention; increase compensation |
| 3 |
OPBG enrollment stalls |
🟢 |
<2 new patients in any 3-month period |
Accelerate multi-center activation |
| 4 |
NUS license dispute |
🟢 |
NUS raises objection to any acquisition term |
Direct IASO CEO → NUS leadership engagement |
| 5 |
EMA rejects CMA pathway |
🟢 |
Negative Type II scientific advice |
Pivot to US FDA pathway |
| 6 |
CD99 preclinical failure |
🟡 |
No in vitro activity in 3+ constructs |
Pivot to CD70; reassess platform thesis |
| 7 |
Cecilia Sim departure |
🟡 |
Resignation notice |
Accelerate knowledge transfer; hire replacement |
| 8 |
Transfer pricing audit |
🟢 |
Tax authority inquiry |
Engage Big 4; present capitalization documentation |
| 9 |
BIOSECURE disrupts WuXi stability testing |
🟢 |
WuXi unable to perform contracted testing |
Transfer stability to IASO or alternative lab |
| 10 |
IPO delay due to integration complexity |
🟡 |
HK IPO prospectus review raises acquisition concerns |
Ring-fence Medisix disclosures; additional due diligence comfort |
5.2 Geopolitical Scenario Planning
| Scenario |
Probability |
Impact |
IASO Response |
| US-CN tech decoupling intensifies |
30% |
Medium |
Maintain SG/EU entities as data and clinical hubs; dual regulatory strategy |
| Singapore tightens biotech FDI rules |
5% |
High |
Established SG entity grandfathered; maintain SG operations and employment |
| EU restricts Chinese clinical trial sponsors |
10% |
High |
OPBG as independent academic sponsor; Medisix SG as nominal sponsor |
| BIOSECURE fully blocks WuXi |
40% |
Low (if insourced) |
Already planned insourcing eliminates dependency |
6. 100-Day, 1-Year, 3-Year Milestones (里程碑规划)
| Timeframe |
Strategic Milestones |
Financial Milestones |
Operational Milestones |
People Milestones |
| Day 1-30 |
Legal close completed; NUS amendment effective; stakeholder communications sent |
Bank accounts transferred; first consolidated report template |
IT access established; insurance bound; IP assignments initiated |
Retention packages activated; Campana agreement signed; IMO Director in SG |
| Day 31-100 |
CD99 preclinical program design finalized; ODD application submitted to EMA; OPBG collaboration agreement signed |
Reporting consolidation complete; TP restructure initiated; FX hedging in place |
LVV process assessment complete; plasmid remanufacture contracted; multi-center site activation begun |
Cecilia knowledge transfer 50% complete; 2 new SG hires initiated; cross-cultural workshop held |
| Year 1 |
23 patients enrolled (PCART7); CD99 in vitro data; PRIME application submitted; US pre-IND meeting |
Integration costs fully absorbed; annual budget established; tax loss utilization plan executed |
LVV process development at IASO complete; GMP batch schedule set; OPBG → IASO CAR-T tech transfer initiated |
SG team at 6-8 FTEs; Campana SAB formalized; employment contracts SG-compliant |
| Year 2 |
CD99 IND filed; CD70 lead candidate selected; PCART7 CMA dossier in preparation; EMA PIP approved |
Revenue from compassionate use/named patient ($1-3M); R&D spend optimization |
LVV GMP validated; commercial CAR-T process validated; supply chain established |
Full R&D team operational; knowledge dependency on individuals reduced |
| Year 3 |
PCART7 CMA approved (EU); CD99 Phase I initiated; CD70 IND preparation; US IND filed for PCART7 |
First significant commercial revenue ($5M+); path to EBITDA breakeven visible |
Commercial manufacturing operational; multi-site supply chain; QA system mature |
Organization self-sustaining; cultural integration normalized; expanded clinical team |
[All source citations refer to documents indexed in 00_Document_Inventory.md]